Last reviewed · How we verify
AXS-02
AXS-02 is a combination of dextromethorphan and quinidine that enhances NMDA receptor antagonism and sigma-1 receptor modulation to reduce neuropathic pain.
AXS-02 is a combination of dextromethorphan and quinidine that enhances NMDA receptor antagonism and sigma-1 receptor modulation to reduce neuropathic pain. Used for Neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN), Fibromyalgia.
At a glance
| Generic name | AXS-02 |
|---|---|
| Sponsor | Axsome Therapeutics, Inc. |
| Drug class | NMDA receptor antagonist / Sigma-1 receptor modulator combination |
| Target | NMDA receptor, Sigma-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
AXS-02 combines dextromethorphan (a dissociative NMDA receptor antagonist) with quinidine (which inhibits dextromethorphan metabolism, increasing its bioavailability and CNS penetration). This combination targets both NMDA receptors and sigma-1 receptors, which are implicated in neuropathic pain signaling. The formulation is designed to provide sustained pain relief in conditions characterized by central sensitization and neuropathic mechanisms.
Approved indications
- Neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN)
- Fibromyalgia
Common side effects
- Dizziness
- Nausea
- Fatigue
- Headache
- Dissociation or cognitive effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions (PHASE3)
- CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |